DelveInsight’s “T-Cell Lymphoma Pipeline Insight 2026” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in the T-Cell Lymphoma pipeline landscape. It covers the T-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the T-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the T-Cell Lymphoma Pipeline @ https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight
Key Takeaways from the T-Cell Lymphoma Pipeline Report
-
On May 20, 2026 – Soligenix announced positive interim results from its ongoing Phase III clinical trial evaluating SGX301 (HyBryte™) for early-stage cutaneous T-cell lymphoma (CTCL), showing significant improvement in skin lesion clearance compared to placebo. The company continues to work closely with the FDA following its NDA submission.
-
On May 12, 2026 – CStone Pharmaceuticals reported breakthrough results from its Phase II study of Sugemalimab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL), demonstrating a robust overall response rate of 68% in heavily pretreated patients.
-
DelveInsight’s T-Cell Lymphoma pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for T-Cell Lymphoma treatment.
-
The leading T-Cell Lymphoma Companies such as Soligenix, CStone Pharmaceuticals, ImmuneOncia Therapeutics, Astex Pharmaceuticals, Corvus Pharmaceuticals, Kyowa Kirin, Bristol-Myers Squibb, Takeda, GlaxoSmithKline, Merck, Secura Bio, Rhizen Pharmaceuticals, Innate Pharma, Verastem Oncology, Affimed, and others.
-
Promising T-Cell Lymphoma Therapies such as SGX301 (HyBryte™), Sugemalimab, IMC-001, Tolinapant, CPI-818, and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ T-Cell Lymphoma Treatment Drugs
The T-Cell Lymphoma Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The T-Cell Lymphoma Pipeline Report also highlights the unmet needs with respect to T-Cell Lymphoma.
T-Cell Lymphoma Overview
T-cell lymphomas are an uncommon and rare subtype of non-Hodgkin lymphomas that can develop in lymphoid tissues such as the lymph nodes and spleen, or outside of lymphoid tissues (i.e., gastrointestinal tract, liver, nasal cavity, skin, and others). This disease group has a poor prognosis compared to their B-cell counterpart. Most T-cell lymphomas develop from mature T cells and usually affect adults, typically people in their mid-60s. They are more common in men than in women.
There are many types of T-cell lymphoma, including T-lymphoblastic lymphoma/leukemia, Peripheral T-cell lymphomas, Cutaneous T-cell lymphomas, Adult T-cell leukemia/lymphoma, Anaplastic Large Cell Lymphoma, and Angioimmunoblastic T-Cell Lymphoma, among others. With around 20 different types of T-cell lymphoma that can start in any area of the body, symptoms between people with T-cell lymphoma can differ greatly.
The most common symptom of lymphoma is swollen lymph nodes. Skin rashes or symptoms involving the skin are more common in some types of T-cell lymphomas. Some common symptoms include fatigue, loss of appetite, pain in bone/joints, muscle weakness, and liver enlargement. Since T-cell lymphomas are rare, they are difficult to diagnose. The diagnosis usually involves biopsy, PET/CT scan, and in some cases, MRI scans.
T-Cell Lymphoma Emerging Drugs ProfileSGX301 (HyBryte™): Soligenix
SGX301 (HyBryte™/synthetic hypericin) is a novel, first-in-class photodynamic therapy utilizing safe visible light for activation. SGX301 is a photodynamic topical therapy using a hypericin ointment activated by visible light which is intended for patients managing early stage CTCL disease progression. HyBryte™ has been granted both Orphan Drug and Fast Track designation in the US, Orphan Drug designation in Europe, and Promising Innovative Medicine designation by the UK Health Authority. The company has submitted a new drug application (NDA) to the US FDA for HyBryte™ (synthetic hypericin) in the treatment of early-stage cutaneous T-cell lymphoma (CTCL).
Sugemalimab: CStone Pharmaceuticals
Sugemalimab is an investigational anti-PD-L1 monoclonal antibody discovered by CStone. As a fully human, full-length anti-PD-L1 monoclonal antibody, sugemalimab mirrors the natural G-type immunoglobulin 4 (IgG4) human antibody, which reduces the risk of immunogenicity and potential toxicities in patients, a unique advantage over similar drugs. In September 2022, the National Medical Products Administration (NMPA) of China accepted and granted priority review to the supplemental new drug application (sNDA) for sugemalimab in the treatment of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL).
IMC-001: ImmuneOncia Therapeutics
IMC-001 (STI-3031) is a fully human anti-PD-L1 IgG1 type monoclonal antibody that has shown promising results in terms of safety and efficacy in the dose-escalation first-in-human study, although the patients were heavily pretreated. IgG1 type antibody targeting PD-L1 on tumors enables unique combinations, such as with an NK cell-based therapy, unique in its property among other PD-1/PD-L1 targeting agents. The drug is in Phase II for the treatment of NK/T-cell lymphoma.
Tolinapant (ASTX660): Astex Pharmaceuticals
Tolinapant (ASTX660) is a potent, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Tolinapant has a unique IAP antagonist molecular profile and has been shown to exert its activity through both IAP antagonism and via an immune-related mechanism. Currently, the drug is being evaluated in Phase I/II (NCT05403450) for patients with peripheral T-cell lymphoma.
CPI-818: Corvus Pharmaceuticals
CPI-818 is an oral, small molecular drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase) and has the potential to provide a platform opportunity with broad applicability across lymphomas, solid tumors, and autoimmune/allergic diseases. The optimal dose of CPI-818 has the potential to induce the activation, differentiation, and expansion of T cells to TH1 helper cells while blocking the deployment of TH2 cells (TH1 skewing). Corvus and its partner in China, Angel Pharmaceuticals, are conducting a Phase I trial in patients with refractory T-cell lymphomas designed to select the optimal dose of CPI-818 and evaluate its safety, pharmacokinetics, target occupancy, immunologic effects, biomarkers, and efficacy.
Explore groundbreaking therapies and clinical trials in the T-Cell Lymphoma Pipeline @ New T-Cell Lymphoma Treatment Drugs
The T-Cell Lymphoma Pipeline Report Provides Insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of T-Cell Lymphoma with aggregate therapies developed by each company for the same.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for T-Cell Lymphoma Treatment.
-
T-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
T-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanisms of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreements, and financing details for future advancement of the T-Cell Lymphoma market.
T-Cell Lymphoma Companies
Soligenix, CStone Pharmaceuticals, ImmuneOncia Therapeutics, Astex Pharmaceuticals, Corvus Pharmaceuticals, Kyowa Kirin, Bristol-Myers Squibb, Takeda, GlaxoSmithKline, Merck, Secura Bio, Rhizen Pharmaceuticals, Innate Pharma, Verastem Oncology, Affimed, and others.
The T-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
T-Cell Lymphoma Products have been categorized under various Molecule types such as:
-
Oligonucleotide
-
Peptide
-
Small molecule
-
Monoclonal antibody
-
Gene therapy
-
Cell therapy
Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ T-Cell Lymphoma Market Drivers and Barriers
Scope of the T-Cell Lymphoma Pipeline Report
-
Coverage: Global
-
T-Cell Lymphoma Companies: Soligenix, CStone Pharmaceuticals, ImmuneOncia Therapeutics, Astex Pharmaceuticals, Corvus Pharmaceuticals, Kyowa Kirin, Bristol-Myers Squibb, Takeda, GlaxoSmithKline, Merck, Secura Bio, Rhizen Pharmaceuticals, Innate Pharma, Verastem Oncology, Affimed, and others.
-
T-Cell Lymphoma Therapies: SGX301 (HyBryte™), Sugemalimab, IMC-001, Tolinapant, CPI-818, and others.
-
T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
-
T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Registered
Download DelveInsight’s in-depth pipeline report today! @ T-Cell Lymphoma Companies, Key Products and Unmet Needs
Table of Contents
-
Introduction
-
Executive Summary
-
T-cell Lymphoma Overview
-
Pipeline Therapeutics
-
Therapeutic Assessment
-
T-cell Lymphoma – DelveInsight’s Analytical Perspective
-
Late Stage Products (Pre-registration)
-
Mid Stage Products (Phase II)
-
Early Stage Products (Phase I/II)
-
Preclinical and Discovery Stage Products
-
Inactive Products
-
T-cell Lymphoma Key Companies
-
T-cell Lymphoma Key Products
-
T-cell Lymphoma Unmet Needs
-
T-cell Lymphoma Market Drivers and Barriers
-
T-cell Lymphoma Future Perspectives and Conclusion
-
T-cell Lymphoma Analyst Views
-
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/